Ensuring Fair Access to Care for Inflammatory Bowel Disease: Obstacles, Approaches, and Future Perspectives

Category	Detail
Condition	Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis
Key Mechanisms	Rising global incidence with disparities in access due to geographic, socioeconomic, racial, and structural factors affecting diagnosis, treatment, and outcomes
Target Population	Global IBD patients, with emphasis on those in low- and middle-income countries, rural areas, disadvantaged socioeconomic groups, and ethnic/racial minorities
Care Setting	Multidisciplinary lifelong care settings including specialist clinics, hospitals, and community-based care with integration of telemedicine and digital health

IBD prevalence is increasing globally, especially in newly industrialized regions, creating new challenges for health systems.
Significant disparities exist in access to specialist care, diagnostics, and advanced therapies between high-income countries and LMICs, and within countries between urban and rural populations.
Equitable care requires addressing social determinants of health, expanding capacity, leveraging cost-effective innovations, and fostering patient and community involvement.

Expand diagnostic capacity including endoscopy and cross-sectional imaging in underserved regions.
Use cost-effective diagnostic innovations such as intestinal ultrasound and telemedicine to improve access.
Increase training and awareness to reduce diagnostic delays and stigma.

Implement multidisciplinary care teams including gastroenterologists, IBD nurses, and allied health specialists.
Ensure equitable access to advanced therapies including biologics, especially for disadvantaged and minority populations.
Embed equity principles into value-based care models and reimbursement policies.

Utilize digital health tools and telemedicine to enhance ongoing monitoring while preventing digital exclusion.
Apply artificial intelligence to support fair resource allocation and personalized care.
Monitor disparities in healthcare utilization and outcomes to guide targeted interventions.

Financial barriers leading to delayed or suboptimal treatment.
Geographic isolation causing limited specialist access and increased emergency care reliance.
Underrepresentation of minorities in clinical trials reducing evidence applicability.
Fragmented care pathways and shortages of specialized staff worsening disparities.

IBD patients globally, with noted disparities in biologic therapy use among ethnic/racial minorities and low socioeconomic groups

Disadvantaged groups are less likely to receive biologics and experience delayed initiation of effective therapies, contributing to worse outcomes.

Address social determinants of health through policy reforms and secure reimbursement mechanisms.
Expand healthcare infrastructure and specialist workforce in LMICs and rural areas.
Leverage telemedicine and digital innovations to improve access and continuity of care.
Promote cultural competence and patient engagement to reduce stigma and improve adherence.
Foster global partnerships to build capacity and share best practices.

Clinical Scorecard: Ensuring Fair Access to Care for Inflammatory Bowel Disease: Obstacles, Approaches, and Future Perspectives